merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>It offers an FDA-approved, safer alternative at a competitive price that could lure customers away from compounded drugs.</answer>
<question_number>2</question_number>
<answer>By selling directly through LillyDirect, bypassing third-party telehealth providers who sell compounded versions.</answer>
<question_number>3</question_number>
<answer>Lack of proper oversight and regulation, compromising safety, quality, and effectiveness.</answer>
<question_number>4</question_number>
<answer>It aims to recapture market share by attracting out-of-pocket buyers with a lower-priced, regulated option despite potentially cannibalizing pen sales.</answer>
<question_number>5</question_number>
<answer>Ensuring tirzepatide is off the shortage list would limit the legal space for mass compounding, reinforcing Lillyâ€™s legal challenges against compounding pharmacies.</answer>
<question_number>6</question_number>
<answer>It demonstrates a move toward direct-to-consumer sales with transparent pricing by removing intermediaries from the supply chain.</answer>
<question_number>7</question_number>
<answer>Medicare patients, lacking insurance coverage for weight-loss drugs, may turn to buying the vials and thereby face the associated safety risks.</answer>
<question_number>8</question_number>
<answer>It positions its FDA-approved vials as a safer alternative, potentially improving safety perceptions compared to compounded tirzepatide.</answer>
<question_number>9</question_number>
<answer>Tirzepatide is listed as being in shortage by the FDA.</answer>
<question_number>10</question_number>
<answer>Offering a lower-priced, regulated version of the drug through its own platform to indirectly undercut compounding pharmacies.</answer>